Eli Lilly and Company has reported a net income of $827.2m, or $0.74 per diluted share, for the fourth quarter ended 31 December 2012 compared to $858.2m, or $0.77 per diluted share, for the fourth quarter ended 31 December 2011.
Total revenue for fourth quarter of 2012 was $5.96bn compared to $6.05bn for the fourth quarter of 2011.
The company reported a net income of $4.09bn, or $3.66 per diluted share, for the year ending 31 December 2012 compared to $4.35bn, or $3.9 per diluted share, for the year ending 31 December 2011.
Total revenue of $22.6bn was reported for 2012 compared to $24.29bn for 2011.
Eli Lilly chairman, president and chief executive officer John Lechleiter said, "Lilly delivered solid financial results in the fourth quarter of 2012, as we successfully offset a large part of the revenue decline from the Zyprexa patent expiration with growth in other products such as Cymbalta, Forteo, Alimta, Effient and our animal health portfolio."
The company expects full-year 2013 earnings per share to be in the range of $4.10 to $4.25 on a reported basis, or $3.82 to $3.97 on a non-GAAP basis.
